DE60320933D1 - Rho-kinase inhibitoren - Google Patents

Rho-kinase inhibitoren

Info

Publication number
DE60320933D1
DE60320933D1 DE60320933T DE60320933T DE60320933D1 DE 60320933 D1 DE60320933 D1 DE 60320933D1 DE 60320933 T DE60320933 T DE 60320933T DE 60320933 T DE60320933 T DE 60320933T DE 60320933 D1 DE60320933 D1 DE 60320933D1
Authority
DE
Germany
Prior art keywords
rho
kinase inhibitors
kinase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60320933T
Other languages
English (en)
Inventor
Dhanapalan Nagarathnam
Uday Khire
Davoud Asgari
Jianxing Shao
Xiao-Gao Liu
Chunguang Wang
Barry Hart
Olaf Weber
Mark Lynch
Lei Zhang
Lei Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Application granted granted Critical
Publication of DE60320933D1 publication Critical patent/DE60320933D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
DE60320933T 2002-01-10 2003-01-10 Rho-kinase inhibitoren Expired - Lifetime DE60320933D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34662802P 2002-01-10 2002-01-10
PCT/US2003/000606 WO2003059913A1 (en) 2002-01-10 2003-01-10 Roh-kinase inhibitors

Publications (1)

Publication Number Publication Date
DE60320933D1 true DE60320933D1 (de) 2008-06-26

Family

ID=23360296

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60320933T Expired - Lifetime DE60320933D1 (de) 2002-01-10 2003-01-10 Rho-kinase inhibitoren

Country Status (8)

Country Link
US (3) US20040014755A1 (de)
EP (1) EP1465900B1 (de)
JP (1) JP4505228B2 (de)
AU (1) AU2003202263A1 (de)
CA (1) CA2472619A1 (de)
DE (1) DE60320933D1 (de)
ES (1) ES2305435T3 (de)
WO (1) WO2003059913A1 (de)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035792A1 (es) * 2001-03-23 2004-07-14 Bayer Corp Compuestos de n-(4-quinazolinil)-n-(1h-indazol-5-il) amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y metodo para prepararlo
US20030125344A1 (en) * 2001-03-23 2003-07-03 Bayer Corporation Rho-kinase inhibitors
DE10357510A1 (de) * 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroarylsubstituierte Benzole
DE102004017438A1 (de) * 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituierte Phenylaminopyrimidine
US7557112B2 (en) * 2004-10-08 2009-07-07 Astellas Pharma Inc. Aromatic-ring-fused pyrimidine derivative
US7576080B2 (en) * 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
WO2006100310A1 (en) 2005-03-25 2006-09-28 Tibotec Pharmaceuticals Ltd Heterobicylic inhibitors of hcv
TW200716631A (en) 2005-05-12 2007-05-01 Tibotec Pharm Ltd Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
WO2006137368A1 (ja) 2005-06-21 2006-12-28 Kowa Co., Ltd. 緑内障の予防又は治療剤
WO2007008926A1 (en) * 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
WO2007008942A2 (en) * 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Phenylamino-acetic acid [1-(pyridin-4-yl)-methylidene]-hydrazide derivatives and related compounds as modulators of g protein-coupled receptor kinases for the treatment of eye diseases
EP1905452B1 (de) 2005-07-12 2013-06-19 Kowa Company, Ltd. Wirkstoff zur prävention oder behandlung von glaukomen
US7910595B2 (en) * 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
CN101340912A (zh) 2005-12-22 2009-01-07 爱尔康研究有限公司 用于治疗rho激酶介导的疾病和病状的(吲唑-5-基)-吡嗪和(1,3-二氢-吲哚-2-酮)-吡嗪
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
JP2009532375A (ja) * 2006-03-30 2009-09-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
EP1874781B9 (de) * 2006-04-19 2010-09-08 Boehringer Ingelheim International GmbH Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
CA2664335C (en) 2006-09-20 2014-12-02 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
MX2009005009A (es) 2006-11-09 2009-09-22 Ardea Biosciences Inc Compuestos heterociclicos biciclicos 4-cianofenilamino sustituidos como inhibidores del virus de inmunodeficiencia humana.
CN101616895A (zh) 2006-12-08 2009-12-30 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
KR101149295B1 (ko) * 2006-12-08 2012-07-05 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
WO2008133753A2 (en) 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
US8455513B2 (en) * 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
BRPI0814777A2 (pt) * 2007-08-08 2015-03-03 Glaxosmithkline Llc Composto, composição farmacêutica, método para tratar um neoplasma, uso de um composto, e, composição farmacêutica.
RU2474434C2 (ru) 2007-08-29 2013-02-10 Сэндзю Фармасьютикал Ко., Лтд. Средство для содействия адгезии роговичных эндотелиальных клеток
ES2569734T3 (es) 2007-09-21 2016-05-12 Array Biopharma, Inc. Derivados de piridin-2-il-tiourea y de piridin-2-il-amina como intermedios para la preparación de piridin-2-il-amino-1,2,4-tiadiazoles activadores de la glucocinasa
AU2008313742B2 (en) 2007-10-19 2013-11-28 Boehringer Ingelheim International Gmbh Heterocycle-substituted piperazino-dihydrothienopyrimidines
US8486948B2 (en) 2007-10-19 2013-07-16 Boehringer Ingelheim International Gmbh Piperazinodihydrothienopyrimidine derivatives
NZ585346A (en) 2007-10-19 2011-09-30 Boehringer Ingelheim Int Substituted piperidino-dihydrothienopyrimidines
SI2215094T1 (sl) * 2007-11-15 2016-05-31 Ym Biosciences Australia Pty Ltd N vsebujoče heterociklične spojine
US8455514B2 (en) * 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
WO2009099982A1 (en) 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US20100272695A1 (en) * 2009-04-22 2010-10-28 Alan Agulnick Cell compositions derived from dedifferentiated reprogrammed cells
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
EP3828172A1 (de) * 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Hemmer mit doppelmechanismus zur behandlung von erkrankungen
BR112012008848A2 (pt) 2009-10-16 2019-09-24 Scripps Research Inst composição, e, método in vitro ou ex vivo para induzir células de mamífero não-pluripotente em células tronco pluripotentes induzidas
AU2010315712B2 (en) 2009-10-19 2014-04-17 FUJIFILM Cellular Dynamics, Inc. Cardiomyocyte production
EP2947073B1 (de) * 2009-10-22 2019-04-03 Fibrotech Therapeutics Pty Ltd Analoga von antifibriotischen mitteln mit kondensierten ringen
AR079705A1 (es) * 2009-12-23 2012-02-15 Biocryst Pharm Inc Compuestos heterociclicos como inhibidores de janus quinasa
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
EP2528606B1 (de) 2010-01-28 2014-09-24 Alexander Levitzki Auf chinazolin basierende t-zell-proliferationshemmer
EP2582794B2 (de) 2010-06-15 2024-04-24 FUJIFILM Cellular Dynamics, Inc. Erzeugung induzierter pluripotenter stammzellen aus kleinen volumina von peripherem blut
TW201219398A (en) * 2010-10-08 2012-05-16 Abbott Lab Furo[3,2-d]pyrimidine compounds
CA2817712C (en) 2010-11-12 2020-03-24 Georgetown University Immortalization of epithelial cells and methods of use
TW201221518A (en) * 2010-11-18 2012-06-01 Glaxo Group Ltd Compounds
WO2012087965A2 (en) 2010-12-22 2012-06-28 Fate Therapauetics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
KR20140006048A (ko) 2011-03-24 2014-01-15 케밀리아 에이비 신규한 피리미딘 유도체
EP2502924A1 (de) 2011-03-24 2012-09-26 Chemilia AB Neue Pyrimidinderivate
DK2694644T3 (en) 2011-03-30 2018-04-16 Cellular Dynamics Int Inc Priming of pluripotent stem cells for neural differentiation
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
JP2014520551A (ja) 2011-07-11 2014-08-25 セルラー ダイナミクス インターナショナル， インコーポレイテッド 細胞のリプログラミング方法およびゲノムの改変方法
MX2014000648A (es) 2011-07-19 2014-09-25 Infinity Pharmaceuticals Inc Compuestos heterociclicos y sus usos.
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9752118B2 (en) 2011-12-06 2017-09-05 Astellas Institute For Regenerative Medicine Method of directed differentiation producing corneal endothelial cells from neural crest stem cells by PDGFB and DKK2, compositions thereof, and uses thereof
US20150044178A1 (en) 2011-12-28 2015-02-12 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
WO2013137491A1 (ja) 2012-03-15 2013-09-19 国立大学法人京都大学 人工多能性幹細胞から心筋および血管系混合細胞群を製造する方法
JP6112733B2 (ja) 2012-04-06 2017-04-12 国立大学法人京都大学 エリスロポエチン産生細胞の誘導方法
EP2711364A1 (de) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl oder benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidine verwendbar für die Behandlung von Krebs
EP2711365A1 (de) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidine verwendbar für die Behandlung von Krebs
US9422267B2 (en) 2012-12-26 2016-08-23 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
EP4218759A3 (de) 2013-03-15 2023-09-06 Aerie Pharmaceuticals, Inc. Kombinationstherapie
US10266807B2 (en) 2013-04-03 2019-04-23 FUJIFILM Cellular Dynamics, Inc. Methods and compositions for culturing endoderm progenitor cells in suspension
JP6461787B2 (ja) 2013-04-12 2019-01-30 国立大学法人京都大学 肺胞上皮前駆細胞の誘導方法
WO2014200115A1 (ja) 2013-06-11 2014-12-18 国立大学法人京都大学 腎前駆細胞の製造方法及び腎前駆細胞を含む医薬
JP6548576B2 (ja) 2013-07-30 2019-07-24 京都府公立大学法人 角膜内皮細胞マーカー
JP6378183B2 (ja) 2013-08-07 2018-08-22 国立大学法人京都大学 膵ホルモン産生細胞の製造法
KR102320537B1 (ko) 2013-09-05 2021-11-01 고쿠리츠 다이가쿠 호진 교토 다이가쿠 신규 도파민 생산 신경 전구 세포의 유도 방법
EP3046557A1 (de) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in kombination mit mapk-signalweg
WO2015054317A1 (en) 2013-10-07 2015-04-16 Kadmon Corporation, Llc Rho kinase inhibitors
US11382904B2 (en) 2013-10-31 2022-07-12 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
TW201605867A (zh) * 2013-11-20 2016-02-16 拜耳製藥公司 噻吩并嘧啶
CN105814195A (zh) 2013-11-27 2016-07-27 京都府公立大学法人 层粘连蛋白应用于角膜内皮细胞培养
EP2905024A1 (de) 2014-02-07 2015-08-12 Institut Quimic De Sarriá Cets, Fundació Privada Pyrido[2,3-d]pyrimidin-7(8H)-on-Derivate zur Behandlung von Flaviviridae Infectionen
EP3114214B1 (de) 2014-03-04 2023-11-01 Fate Therapeutics, Inc. Verbesserte neuprogrammierungsverfahren und zellkulturplattformen
US9694036B2 (en) 2014-03-21 2017-07-04 Cellular Dynamics International, Inc. Production of midbrain dopaminergic neurons and methods for the use thereof
EP3147353B1 (de) 2014-05-21 2022-03-30 Kyoto University Verfahren zur herstellung von pankreasblasten und pankreaskrankheitsbehandlungsmittel mit pankreasblasten
CN107075469A (zh) 2014-06-27 2017-08-18 加利福尼亚大学董事会 培养的哺乳动物角膜缘干细胞、其产生方法和其用途
US10711249B2 (en) 2014-12-26 2020-07-14 Kyoto University Method for inducing hepatocytes
CN104530078B (zh) * 2015-01-27 2017-03-22 山东大学 一种噻吩并[3,2‑d]嘧啶衍生物及其制备方法与应用
KR102598772B1 (ko) 2015-04-03 2023-11-03 프로파제닉스 인크. 상피 세포의 생체외 증식
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
US10729691B2 (en) 2015-06-26 2020-08-04 Kadmon Corporation, Llc Treatment of infectious diseases with glucose uptake inhibitors
CA2988461A1 (en) * 2015-06-26 2016-12-29 Dana-Farber Cancer Institute, Inc. Fused bicyclic pyrimidine derivatives and uses thereof
EP3313825A4 (de) 2015-06-26 2019-03-13 Kadmon Corporation, LLC Glucoseaufnahmehemmer
WO2017044454A1 (en) 2015-09-11 2017-03-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
CN117737124A (zh) 2015-10-16 2024-03-22 菲特治疗公司 用于诱导和维护基态多能性的平台
WO2017075389A1 (en) 2015-10-30 2017-05-04 The Regents Of The Universtiy Of California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
AU2015414743B2 (en) 2015-11-17 2019-07-18 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
AU2016362394B2 (en) * 2015-12-03 2021-01-14 Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. Heterocycle compounds and uses thereof
AU2016362390B2 (en) * 2015-12-03 2021-11-11 Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. Thieno-pyrimidine derivatives and uses thereof
EP3394056B1 (de) 2015-12-22 2021-04-14 Shy Therapeutics LLC Verbindungen zur behandlung von krebs und entzündungskrankheiten
PL3416658T3 (pl) 2016-02-15 2023-09-04 Kyoto Prefectural Public University Corporation Funkcjonalna ludzka komórka śródb‎łonka rogówki i jej zastosowanie
JP7011260B2 (ja) 2016-04-22 2022-02-10 国立大学法人京都大学 ドーパミン産生神経前駆細胞の製造方法
CN107652273B (zh) * 2016-07-26 2020-05-01 沈阳药科大学 嘧啶类衍生物及其制备方法和应用
ES2901379T3 (es) 2016-08-16 2022-03-22 Fujifilm Cellular Dynamics Inc Métodos para diferenciar células pluripotentes
US11389441B2 (en) 2016-08-31 2022-07-19 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
EP3577103A1 (de) 2017-02-03 2019-12-11 Certa Therapeutics Pty Ltd. Antifibrotische verbindungen
AU2018243687C1 (en) 2017-03-31 2020-12-24 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
KR20230150412A (ko) 2017-05-25 2023-10-30 고쿠리츠 다이가쿠 호진 교토 다이가쿠 중간 중배엽 세포로부터 신장 전구 세포로의 분화 유도 방법 및 다능성 줄기세포로부터 신장 전구 세포로의 분화 유도 방법
US10588894B2 (en) 2017-06-21 2020-03-17 SHY Therapeutics LLC Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN111217797B (zh) 2017-06-30 2021-02-05 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
US10323023B2 (en) 2017-06-30 2019-06-18 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
US10329282B2 (en) 2017-06-30 2019-06-25 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
EA202090572A1 (ru) * 2017-09-01 2020-07-06 Кадмон Корпорейшн, Ллк ИНГИБИТОРЫ Rho-АССОЦИИРОВАННОЙ, СОДЕРЖАЩЕЙ СУПЕРСПИРАЛЬ ПРОТЕИНКИНАЗЫ
CA3080691C (en) 2017-11-10 2022-11-15 Regenesis Science Co., Ltd. Method for producing cultured cell, and method for producing therapeutic agent for spinal cord injury disease
CN111788300A (zh) 2017-12-28 2020-10-16 株式会社钟化 细胞聚集抑制剂
EP3733840A4 (de) 2017-12-28 2021-11-24 Kaneka Corporation Pluripotenter stammzellaggregationsinhibitor
EP3733837A4 (de) 2017-12-28 2021-10-06 Kaneka Corporation Mittel zur förderung der zellaggregation
CA3096870A1 (en) 2018-02-19 2019-08-22 Sumitomo Dainippon Pharma Co., Ltd. Cell aggregate, mixture of cell aggregates, and method for preparing same
US20210332329A1 (en) 2018-07-23 2021-10-28 Kyoto University Novel renal progenitor cell marker and method for concentrating renal progenitor cells using same
WO2020041065A1 (en) 2018-08-20 2020-02-27 Propagenix Inc. Epithelial cell spheroids
CA3110661A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
CN113056556A (zh) 2018-08-31 2021-06-29 学校法人同志社 用于对眼细胞进行保存或培养的组合物以及方法
CA3112391A1 (en) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2020071438A1 (ja) 2018-10-02 2020-04-09 学校法人同志社 角膜内皮細胞を保存するための方法および容器
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
CA3119426A1 (en) * 2018-11-30 2020-06-04 Celularity Inc. Aromatic compounds for use in activating hematopoietic stem and progenitor cells
US20220056413A1 (en) 2018-12-21 2022-02-24 Kyoto University Lubricin-localized cartilage-like tissue, method for producing same and composition comprising same for treating articular cartilage damage
WO2020193802A1 (en) 2019-03-28 2020-10-01 Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe Polymeric conjugates and uses thereof
JPWO2020203538A1 (de) 2019-03-29 2020-10-08
CN113811316A (zh) 2019-05-15 2021-12-17 味之素株式会社 神经嵴细胞或角膜上皮细胞的纯化方法
JPWO2021172554A1 (de) 2020-02-27 2021-09-02
EP4142879A1 (de) 2020-04-27 2023-03-08 Novartis AG Verfahren und zusammensetzungen zur augenzelltherapie
WO2022149616A1 (ja) 2021-01-08 2022-07-14 国立大学法人京都大学 ネフロン前駆細胞を拡大培養するための培地、ネフロン前駆細胞を拡大培養する方法、腎臓オルガノイドの製造方法
WO2022216911A1 (en) 2021-04-07 2022-10-13 FUJIFILM Cellular Dynamics, Inc. Dopaminergic precursor cells and methods of use
CA3216719A1 (en) 2021-05-03 2022-11-10 Astellas Institute For Regenerative Medicine Methods of generating mature corneal endothelial cells
CA3222761A1 (en) 2021-06-10 2022-12-15 Ajinomoto Co., Inc. Method for producing mesenchymal stem cells
WO2023017848A1 (ja) 2021-08-11 2023-02-16 国立大学法人京都大学 腎間質前駆細胞の製造方法並びにエリスロポエチン産生細胞、およびレニン産生細胞の製造方法
AU2022343749A1 (en) 2021-09-13 2024-03-28 FUJIFILM Cellular Dynamics, Inc. Methods for the production of committed cardiac progenitor cells
WO2023069949A1 (en) 2021-10-18 2023-04-27 Evia Life Sciences Inc. Compositions and methods of use thereof for treating liver fibrosis
WO2023067394A2 (en) 2021-10-22 2023-04-27 Evia Life Sciences Inc. Methods for making extracellular vesicles, and compositions and methods of use thereof
WO2024073776A1 (en) 2022-09-30 2024-04-04 FUJIFILM Cellular Dynamics, Inc. Methods for the production of cardiac fibroblasts

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642347A (en) * 1985-05-21 1987-02-10 American Home Products Corporation 3(2-quinolinylalkoxy)phenols
US5245038A (en) * 1987-11-06 1993-09-14 Baxter Diagnostics Inc. Fluorescent poly(arylpyridine) rare earth chelates
IL89029A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
ATE156120T1 (de) * 1991-02-07 1997-08-15 Roussel Uclaf Bizyklische stickstoffverbindungen, ihre herstellung, erhaltene zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
US6004979A (en) * 1991-02-07 1999-12-21 Hoechst Marion Roussel Nitrogenous bicycles
US5245036A (en) * 1992-05-07 1993-09-14 Dowelanco Process for the preparation of 4-phenoxyquinoline compounds
US5972598A (en) * 1992-09-17 1999-10-26 Board Of Trustess Of The University Of Illinois Methods for preventing multidrug resistance in cancer cells
EP1195372A1 (de) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-Heterozyklisch substitutierte Benzamid Deriviate mit antihypertensiver Wirkung
US5840695A (en) * 1994-10-07 1998-11-24 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
EP0831829B1 (de) * 1995-06-07 2003-08-20 Pfizer Inc. Heterocyclische kondensierte pyrimidin-derivate
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US5906819A (en) * 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
DE19608653A1 (de) * 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AU3766897A (en) * 1996-07-13 1998-02-09 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
DK0956865T4 (da) * 1996-08-12 2010-11-22 Mitsubishi Tanabe Pharma Corp Medikamenter omfattende Rho-kinaseinhibitor
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US5885803A (en) * 1997-06-19 1999-03-23 Incyte Pharmaceuticals, Inc. Disease associated protein kinases
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
CA2214841A1 (en) 1997-10-31 1999-04-30 Lisa Mckerracher Rho antagonists and their use to block inhibition of neurite outgrowth
AU9454198A (en) * 1997-11-11 1999-05-31 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS50087B (sr) * 1998-06-19 2009-01-22 Pfizer Products Inc., Pirolo (2,3-d) pirimidin jedinjenja
EP1459743B9 (de) 1998-08-17 2012-08-01 Senju Pharmaceutical Co., Ltd. Verbindung zur Vorbeugung und Behandlung von Glaukoma
JP2002523403A (ja) * 1998-08-21 2002-07-30 パーカー ヒューズ インスティテュート キナゾリン誘導体
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
SE515247C2 (sv) 1998-09-04 2001-07-02 Alfa Laval Agri Ab Djurbås med fösningsorgan
KR20010099890A (ko) * 1998-12-23 2001-11-09 빌프리더 하이더 황색도 지수가 낮은 폴리카르보네이트
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
DE19911510A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2000057914A1 (fr) 1999-03-25 2000-10-05 Santen Pharmaceutical Co., Ltd. Agents permettant d'abaisser la tension oculaire
EP1163910B1 (de) 1999-03-25 2007-09-26 Mitsubishi Pharma Corporation Rho-kinase-inhibitoren für die vorbeugung oder behandlung von interstitieller pneumonie und pulmonaler fibrose
CN1358102A (zh) 1999-04-22 2002-07-10 三菱制药株式会社 血管狭窄预防治疗药
US6794398B1 (en) 1999-04-27 2004-09-21 Mitsubishi Pharma Corporation Preventive/remedies for liver diseases
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
WO2001028561A1 (en) 1999-10-21 2001-04-26 Merck & Co., Inc. Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
MXPA03002410A (es) 2000-09-20 2003-06-19 Merck Patent Gmbh 4-amino-quinazolinas.
JP5305553B2 (ja) 2000-10-12 2013-10-02 ユニバーシティー オブ ロチェスター 癌細胞の増殖を阻害する組成物
US20020132832A1 (en) 2001-01-05 2002-09-19 Mills Thomas M. Treatment of erectile dysfunction
US20030125344A1 (en) * 2001-03-23 2003-07-03 Bayer Corporation Rho-kinase inhibitors
ATE381557T1 (de) * 2002-01-23 2008-01-15 Bayer Pharmaceuticals Corp Rho-kinase inhibitoren

Also Published As

Publication number Publication date
US7648986B2 (en) 2010-01-19
EP1465900B1 (de) 2008-05-14
US20070238741A1 (en) 2007-10-11
WO2003059913A1 (en) 2003-07-24
CA2472619A1 (en) 2003-07-24
EP1465900A1 (de) 2004-10-13
JP2005523251A (ja) 2005-08-04
AU2003202263A1 (en) 2003-07-30
US20040014755A1 (en) 2004-01-22
JP4505228B2 (ja) 2010-07-21
US20100216789A1 (en) 2010-08-26
ES2305435T3 (es) 2008-11-01

Similar Documents

Publication Publication Date Title
DE60320933D1 (de) Rho-kinase inhibitoren
DE60211317D1 (de) Rho-kinase inhibitoren
DE60218138D1 (de) Rho-kinase inhibitoren
ATE505471T1 (de) Azaindol-kinaseinhibitoren
DE602004018837D1 (de) Ptidase-iv-inhibitoren
DE60234125D1 (de) E inhibitoren
NO20041293D0 (no) Alkyn-aryl-fosfodiesterase-4-inhibitorer
DK1505963T3 (da) Hepatitis C-inhibitorer
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE443054T1 (de) Cyano-pyrrolidine als dpp-iv inhibitoren
NO20054852D0 (no) GFAT inhibitorer
IS7599A (is) Heterósýklískir kínasatálmar
NO20055680D0 (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
ATE333454T1 (de) Metalloproteinaseinhibitoren
EE200300439A (et) Metalloproteinaasi inhibiitorid
DK1569712T3 (da) Forbindelsesindretning
ATE308544T1 (de) N-substituiete heteroaryloxy-aryl-spiro- pyrimidine-2,4,6-trion metalloproteinase inhibitoren
ATE286049T1 (de) Pyridazinonaldose reductase inhibitoren
ATE304015T1 (de) Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren
EE200300450A (et) Metalloproteinaasi inhibiitorid
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
DK1501804T3 (da) Isoquinolinderivat MAO-B-inhibitorer
NO20032807L (no) Substituerte 8-arylkinolin-fosfodiesterase-4-inhibitorer
NO20044269L (no) Smamolekylaere inntrengningsinhibitorer
NO20034109L (no) Parafininhibitor-komposisjon

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 1335, DE